322 related articles for article (PubMed ID: 19260807)
1. Stem cell patents--reexamination/litigation--the last 5 years.
Shyntum Y; Kalkreuter E
Tissue Eng Part B Rev; 2009 Mar; 15(1):87-90. PubMed ID: 19260807
[TBL] [Abstract][Full Text] [Related]
2. Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.
Pillai X; Kinney WA
Curr Top Med Chem; 2010; 10(18):1929-36. PubMed ID: 20615184
[TBL] [Abstract][Full Text] [Related]
3. Patentability of Stem Cells in the United States.
Fendrick SE; Zuhn DL
Cold Spring Harb Perspect Med; 2015 Aug; 5(12):. PubMed ID: 26292987
[TBL] [Abstract][Full Text] [Related]
4. Nonobviousness of pharmaceutical inventions: implications for patent prosecution and litigation.
Dhulap S; Kulkarni M
Pharm Pat Anal; 2019 Jul; 8(4):91-107. PubMed ID: 31414965
[TBL] [Abstract][Full Text] [Related]
5. The ethics of patenting human embryonic stem cells.
Chapman AR
Kennedy Inst Ethics J; 2009 Sep; 19(3):261-88. PubMed ID: 19886524
[TBL] [Abstract][Full Text] [Related]
6. Stem cell patents after the america invents act.
Sherkow JS; Scott CT
Cell Stem Cell; 2015 May; 16(5):461-4. PubMed ID: 25957901
[TBL] [Abstract][Full Text] [Related]
7. Patent first, ask questions later: morality and biotechnology in patent law.
Bagley MA
William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677
[TBL] [Abstract][Full Text] [Related]
8. Revocation of European patent for neural progenitors highlights patent challenges for inventions relating to human embryonic stem cells.
Rigby B
Expert Opin Ther Pat; 2013 Nov; 23(11):1395-8. PubMed ID: 24079708
[TBL] [Abstract][Full Text] [Related]
9. WARF's stem cell patents and tensions between public and private sector approaches to research.
Golden JM
J Law Med Ethics; 2010; 38(2):314-31. PubMed ID: 20579254
[TBL] [Abstract][Full Text] [Related]
10. Challenges to human embryonic stem cell patents.
Plomer A; Taymor KS; Scott CT
Cell Stem Cell; 2008 Jan; 2(1):13-7. PubMed ID: 18371416
[TBL] [Abstract][Full Text] [Related]
11. Patent prosecution strategies for stem cell related applications.
Kumar R; Yeh JJ; Fernandez D; Hansen N
J Biomol Screen; 2007 Sep; 12(6):769-74. PubMed ID: 17848639
[TBL] [Abstract][Full Text] [Related]
12. The use of Food and Drug Administration 510(k) notifications in patent litigation.
Tolomeo DE
Food Drug Law J; 2004; 59(4):465-77. PubMed ID: 15875346
[TBL] [Abstract][Full Text] [Related]
13. Gene patents, patenting life and the impact of court rulings on US stem cell patents and research.
Matthews KR; Cuchiara ML
Regen Med; 2014 Mar; 9(2):191-200. PubMed ID: 24750060
[TBL] [Abstract][Full Text] [Related]
14. The attack of the clones: patent law and stem cell research.
Rimmer M
J Law Med; 2003 May; 10(4):488-505. PubMed ID: 12852321
[TBL] [Abstract][Full Text] [Related]
15. The end of DNA patents in the United States?
Webber P
Expert Opin Ther Pat; 2013 Dec; 23(12):1525-7. PubMed ID: 24138004
[TBL] [Abstract][Full Text] [Related]
16. KSR v. Teleflex. Part 2: Impact of U.S Supreme Court Patent Law on Canadian and global systems-based innovation ecologies.
Bouchard RA
Health Law J; 2007; 15():247-94. PubMed ID: 19702185
[No Abstract] [Full Text] [Related]
17. Patents and innovation in cancer therapeutics: lessons from CellPro.
Bar-Shalom A; Cook-Deegan R
Milbank Q; 2002; 80(4):637-76, iii-iv. PubMed ID: 12532643
[TBL] [Abstract][Full Text] [Related]
18. Strategies for stem cell patent applications in the light of recent court cases.
Eyre DE; Schlich GW
Pharm Pat Anal; 2015; 4(6):431-41. PubMed ID: 26580992
[TBL] [Abstract][Full Text] [Related]
19. The stem cell patent landscape as relevant to cancer vaccines.
Wang SJ
Hum Vaccin; 2011 Oct; 7(10):1100-8. PubMed ID: 21957493
[TBL] [Abstract][Full Text] [Related]
20. Life forms protectable as subjects of U.S. patents -- microbes to animals (perhaps).
Hodgins DS
Biomater Artif Cells Artif Organs; 1989; 17(2):205-24. PubMed ID: 2775879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
